We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
Read MoreHide Full Article
Key Takeaways
ANI Pharmaceuticals trades at 10.10X forward earnings, far below sub-industry and sector averages.
ANIP's $93 target hinges on Cortrophin growth and ophthalmology stabilizing after 2025 headwinds.
ANI Pharmaceuticals guides 2026 EPS of $8.83-$9.34 and Cortrophin revenue of $540-$575 million.
ANI Pharmaceuticals (ANIP - Free Report) has been steadier than its broader sector this year, but it has not fully kept pace with its closest peer set. Shares are up 2.5% year to date, versus a 3.5% gain for the Zacks sub-industry, while the sector is down 4.8% over the same period.
That relative gap matters because the stock has also underperformed the industry year to date. The setup leaves investors weighing a seemingly discounted valuation against the need for clean execution in 2026.
ANIP Stock Has Lagged Its Sub-Industry Year to Date
The year-to-date snapshot is mixed. ANIP’s 2.5% gain beats a sector that is down 4.8%, but it trails the Zacks sub-industry’s 3.5% rise.
The stock’s year-to-date underperformance versus the industry adds a second layer to the discussion. It suggests the market is not fully rewarding the company’s strategic shift toward higher-margin specialty therapies yet.
That disconnect is why valuation has become the central debate. If business momentum holds, the current multiple can look conservative. If execution slips, the discount can persist.
ANI Pharma’s Valuation vs Zacks Peer Multiples
ANIP trades at 10.10X forward 12-month earnings. That compares with 38.43X for the Zacks sub-industry and 20.26X for the Zacks sector.
This gap is large enough to draw two conclusions at once. The first is that the stock is priced well below peer group multiples. The second is that investors are assigning meaningful risk to the outlook, especially given the company’s concentrated growth drivers.
The comparison also frames why the stock can look “cheap” without being automatically “undervalued.” The market is asking what has to go right for a rerating toward peer levels.
ANIP’s Forward P/E and Price-to-Sales in Context
Looking at ANIP’s own history, the forward earnings multiple sits near the lower end of its five-year range. As of 04/17/2026, the stock’s forward 12-month price-to-earnings ratio is 10.1 versus a five-year high of 61.11, a low of 7.4 and a median of 15.69.
On a forward 12-month price-to-sales basis, the current multiple is 1.64 versus a five-year median of 1.94. That reads as modestly discounted relative to the stock’s longer-term norm.
The contrast shows up in price-to-book. ANIP’s trailing 12-month price-to-book ratio is 3.35 versus a five-year median of 2.77. That metric screens elevated versus history, even as earnings and sales multiples look lower.
ANI Pharma’s $93 Target and What It Implies
The stated $93.00 price target is tied directly to earnings. It reflects 9.76X forward 12-month earnings, keeping the thesis anchored in profit delivery rather than a broad multiple expansion story.
For the target to be supported, two operational items stand out. First, the company needs sustained scale in Cortrophin Gel, which has become the focus of the specialty strategy and the primary growth engine. Second, the ophthalmology franchise needs to stabilize after 2025 headwinds tied to reimbursement challenges and elevated inventories at physician offices, with a return to growth expected in 2026.
Those two variables largely determine whether the current discount is a temporary skepticism gap or a longer-lasting market verdict.
Management reaffirmed full-year 2026 guideposts that can be translated into an investor checklist. Adjusted non-GAAP earnings per share are guided to $8.83-$9.34. Adjusted non-GAAP EBITDA is expected at $275-$290 million.
Profitability is also framed clearly. Adjusted gross margin is guided to 59.3%-60.3%, which puts execution on pricing, mix, and costs in focus.
Cortrophin is the primary sensitivity driver. Management guided Cortrophin revenue to $540-$575 million, making performance in this franchise the key swing factor for confidence in the year.
ANI Pharma’s Balance Sheet and Debt Profile
The liquidity and leverage snapshot is straightforward. Cash was about $286 million at Dec. 31, 2025. Short-term debt was $17 million, and long-term debt was $600 million.
A key point is near-term coverage. The company has enough cash to pay debt maturing in the next 12 months, which can reduce refinancing pressure and keep attention on operating execution.
That said, leverage still matters, especially in a business where competitive dynamics can change quickly across specialty and branded markets.
ANIP’s Concentrated Customer Base Adds Risk
Distribution concentration is a tangible risk factor. In 2025, three wholesale customers accounted for 53% of total net revenues and represented 64% of accounts receivable.
The broader consolidation trend among wholesale distributors and pharmacy chains can increase purchasing leverage. That can translate into pricing pressure and margin risk, particularly if volume is concentrated in fewer hands.
This is not an abstract concern. It is a structural factor that can influence the durability of profitability, even in years when demand trends are favorable.
ANI Pharma’s Bull Case Depends on Cortrophin
The bull case ultimately ties valuation back to the business mix. Cortrophin Gel is the growth engine and the central pillar of the specialty strategy. The Generics segment is no longer the primary growth driver, but it provides a stable cash flow base and downside support through steady launches and niche execution.
Ophthalmology is the swing factor for sentiment. After a 2025 “reset year,” expectations hinge on a return to growth in 2026 and a cleaner market access backdrop. If that recovery materializes alongside continued Cortrophin momentum, the current multiple can look more like a starting point than a ceiling.
AbbVie (ABBV - Free Report) and Regeneron Pharmaceuticals (REGN - Free Report) underscore the competitive bar in ophthalmology, where established therapies can shape share and pricing dynamics.
View the Zacks #1 Rank List
Image: Bigstock
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
Key Takeaways
ANI Pharmaceuticals (ANIP - Free Report) has been steadier than its broader sector this year, but it has not fully kept pace with its closest peer set. Shares are up 2.5% year to date, versus a 3.5% gain for the Zacks sub-industry, while the sector is down 4.8% over the same period.
That relative gap matters because the stock has also underperformed the industry year to date. The setup leaves investors weighing a seemingly discounted valuation against the need for clean execution in 2026.
ANIP Stock Has Lagged Its Sub-Industry Year to Date
The year-to-date snapshot is mixed. ANIP’s 2.5% gain beats a sector that is down 4.8%, but it trails the Zacks sub-industry’s 3.5% rise.
The stock’s year-to-date underperformance versus the industry adds a second layer to the discussion. It suggests the market is not fully rewarding the company’s strategic shift toward higher-margin specialty therapies yet.
That disconnect is why valuation has become the central debate. If business momentum holds, the current multiple can look conservative. If execution slips, the discount can persist.
ANI Pharma’s Valuation vs Zacks Peer Multiples
ANIP trades at 10.10X forward 12-month earnings. That compares with 38.43X for the Zacks sub-industry and 20.26X for the Zacks sector.
This gap is large enough to draw two conclusions at once. The first is that the stock is priced well below peer group multiples. The second is that investors are assigning meaningful risk to the outlook, especially given the company’s concentrated growth drivers.
The comparison also frames why the stock can look “cheap” without being automatically “undervalued.” The market is asking what has to go right for a rerating toward peer levels.
ANIP’s Forward P/E and Price-to-Sales in Context
Looking at ANIP’s own history, the forward earnings multiple sits near the lower end of its five-year range. As of 04/17/2026, the stock’s forward 12-month price-to-earnings ratio is 10.1 versus a five-year high of 61.11, a low of 7.4 and a median of 15.69.
On a forward 12-month price-to-sales basis, the current multiple is 1.64 versus a five-year median of 1.94. That reads as modestly discounted relative to the stock’s longer-term norm.
The contrast shows up in price-to-book. ANIP’s trailing 12-month price-to-book ratio is 3.35 versus a five-year median of 2.77. That metric screens elevated versus history, even as earnings and sales multiples look lower.
ANI Pharma’s $93 Target and What It Implies
The stated $93.00 price target is tied directly to earnings. It reflects 9.76X forward 12-month earnings, keeping the thesis anchored in profit delivery rather than a broad multiple expansion story.
For the target to be supported, two operational items stand out. First, the company needs sustained scale in Cortrophin Gel, which has become the focus of the specialty strategy and the primary growth engine. Second, the ophthalmology franchise needs to stabilize after 2025 headwinds tied to reimbursement challenges and elevated inventories at physician offices, with a return to growth expected in 2026.
Those two variables largely determine whether the current discount is a temporary skepticism gap or a longer-lasting market verdict.
ANI Pharmaceuticals, Inc. Price and Consensus
ANI Pharmaceuticals, Inc. price-consensus-chart | ANI Pharmaceuticals, Inc. Quote
ANIP’s 2026 EPS and EBITDA Guideposts
Management reaffirmed full-year 2026 guideposts that can be translated into an investor checklist. Adjusted non-GAAP earnings per share are guided to $8.83-$9.34. Adjusted non-GAAP EBITDA is expected at $275-$290 million.
Profitability is also framed clearly. Adjusted gross margin is guided to 59.3%-60.3%, which puts execution on pricing, mix, and costs in focus.
Cortrophin is the primary sensitivity driver. Management guided Cortrophin revenue to $540-$575 million, making performance in this franchise the key swing factor for confidence in the year.
ANI Pharma’s Balance Sheet and Debt Profile
The liquidity and leverage snapshot is straightforward. Cash was about $286 million at Dec. 31, 2025. Short-term debt was $17 million, and long-term debt was $600 million.
A key point is near-term coverage. The company has enough cash to pay debt maturing in the next 12 months, which can reduce refinancing pressure and keep attention on operating execution.
That said, leverage still matters, especially in a business where competitive dynamics can change quickly across specialty and branded markets.
ANIP’s Concentrated Customer Base Adds Risk
Distribution concentration is a tangible risk factor. In 2025, three wholesale customers accounted for 53% of total net revenues and represented 64% of accounts receivable.
The broader consolidation trend among wholesale distributors and pharmacy chains can increase purchasing leverage. That can translate into pricing pressure and margin risk, particularly if volume is concentrated in fewer hands.
This is not an abstract concern. It is a structural factor that can influence the durability of profitability, even in years when demand trends are favorable.
ANI Pharma’s Bull Case Depends on Cortrophin
The bull case ultimately ties valuation back to the business mix. Cortrophin Gel is the growth engine and the central pillar of the specialty strategy. The Generics segment is no longer the primary growth driver, but it provides a stable cash flow base and downside support through steady launches and niche execution.
Ophthalmology is the swing factor for sentiment. After a 2025 “reset year,” expectations hinge on a return to growth in 2026 and a cleaner market access backdrop. If that recovery materializes alongside continued Cortrophin momentum, the current multiple can look more like a starting point than a ceiling.
AbbVie (ABBV - Free Report) and Regeneron Pharmaceuticals (REGN - Free Report) underscore the competitive bar in ophthalmology, where established therapies can shape share and pricing dynamics.
ANIP’s Zacks Rank
ANI Pharmaceuticals currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.